F-star Therapeutics, Inc. Common Stock
FSTX
FSTX was delisted on the 8th of March, 2023.
18 hedge funds and large institutions have $10.5M invested in F-star Therapeutics, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
64% more funds holding
Funds holding: 11 → 18 (+7)
49% more capital invested
Capital invested by funds: $7.05M → $10.5M (+$3.44M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TA
Tiedemann Advisors
New York
|
+$2.66M |
| 2 |
Millennium Management
New York
|
+$557K |
| 3 |
PCM
Parsons Capital Management
Providence,
Rhode Island
|
+$328K |
| 4 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
+$321K |
| 5 |
Luther King Capital Management (LKCM)
Fort Worth,
Texas
|
+$267K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$876K |
| 2 |
SAM
Silvercrest Asset Management
New York
|
-$777K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$408K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$219K |
FSTX Hedge Fund Activity: Q1 2017 in Review
18 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q1 2017, worth a combined $10.5M — up 49% from $7.05M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new FSTX positions and 3 closed out — a net gain of 8 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Tiedemann Advisors, opening a new position worth an estimated $2.66M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $876K sold.
- 18 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q1 2017, up from 11 in Q4 2016.
- Funds reported $10.5M of F-star Therapeutics, Inc. Common Stock stock for Q1 2017, up 49% quarter-over-quarter.
- 11 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q1 2017 and 3 closed out, a net change of +8 holders.
- The largest F-star Therapeutics, Inc. Common Stock buyer in Q1 2017 was Tiedemann Advisors, an estimated $2.66M added.
- The largest F-star Therapeutics, Inc. Common Stock seller in Q1 2017 was Susquehanna International Group, an estimated $876K sold.
Based on aggregated 13F filings for Q1 2017.